The Business Plan For The Epilepsy Drugs Market has shown significant growth over the past few years due to the increase in the global epilepsy patient population. Epilepsy drugs are used for the treatment of epilepsy disorder which is caused by unusual electrical activity in the brain. These drugs help in reducing seizure frequency and maintaining normal neurological functions. Some of the commonly prescribed epilepsy drugs includes phenytoin, carbamazepine, lamotrigine, valproate and clobazam. The anti-epileptic drugs offer anti-seizure effects, prevents further epilepsy episodes, and helps in improving the quality of life for epilepsy patients. The growing prevalence of epilepsy worldwide along with rising awareness about epilepsy care and management is fueling the demand of epilepsy drugs globally.
The Global epilepsy drugs market is estimated to be valued at US$ 10.31 Bn in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the epilepsy drugs are Pfizer Inc., Sumitomo Pharma Co., Ltd., Novartis AG, Abbott, GSK plc., Teva Pharmaceutical Industries Ltd., Sanofi, Takeda Pharmaceutical Company Limited, Marinus Pharmaceuticals, Inc, Eisai Co., Ltd, DAIICHI SANKYO COMPANY, LIMITED, Mylan N.V., Dr. Reddy’s Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Neurelis, Inc., and Supernus Pharmaceuticals, Inc. The key players are mainly focusing on new product developments and launches to expand their product portfolios. For instance, in 2022, Marinus Pharmaceuticals launched ganaxolone for treatment of seizures associated with CDKL5 deficiency disorder.
The Epilepsy Drugs Market Growth investment in R&D of novel drug molecules and rising awareness regarding epilepsy care provide significant growth opportunities in the market. Further, growing geriatric population prone to epilepsy and improving healthcare infrastructure in developing regions will augment the global expansion of epilepsy drugs market.
The increasing prevalence of epilepsy worldwide due to head injuries, brain tumor, stroke, infections of the central nervous system, and genetic predisposition is the major market driver. As per the World Health Organization, around 50 million people globally have epilepsy, making it one of the most common neurological diseases internationally. This wide patient pool needing effective epilepsy care and management fuels the demand of epilepsy drugs.
PEST Analysis
Political: The production and distribution of epilepsy drugs is regulated by various government authorities and regulations. Changes in healthcare policies and regulations impact the sales and demand for epilepsy drugs in a region.
Economic: Economic slowdowns can negatively impact the disposable income of patients and their ability and willingness to spend on expensive branded drugs. Recessions may boost demand for affordable generic alternatives.
Social: Epilepsy Drugs Market Size and Trends in social stigma around neurological disorders is reducing worldwide, aiding awareness and timely diagnosis. Support groups help patients manage their condition better and adhere to treatment plans.
Technological: Advances in biologics, genetics, and drug delivery mechanisms help develop newer targeted therapies. Technologies enabling remote monitoring help patients and reduce hospital visits. Precision medicine tailored to individual genetic profiles may yield personalized treatments.
The North American market accounted for the highest value share in the epilepsy drugs market in 2024 owing to growing prevalence, awareness, favorable reimbursement scenarios, and developed healthcare infrastructure in countries like the US and Canada.
The Asia Pacific region is expected to be the fastest growing market during the forecast period driven by rising disposable incomes, growing disease burden, increasing healthcare spending and expanding healthcare facilities in developing economies of India, China and others.
Explore More Related Article On- Gastroesophageal Reflux Disease Treatment Devices Market
For Deeper Insights, Find the Report in the Language that You want.
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
0 comment